Fig. 1 · Structure

Documents & Downloads

PSI-6206

Cat. No. A11530 CAS 863329-66-2

HCV RNA polymerase inhibitor

PSI-6206 is the deaminated derivative of PSI-6130, which is a potent inhibitor of hepatitis C virus (HCV) replication in the subgenomic HCV reolicon system.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
Huh-7 CC50 > 100 μM Cytotoxic concentration against HCV replication RNA levels in Huh7 cells determined by HCV replicon assay [PMID: 16107149]
Huh-7 EC50 > 89 μM Antiviral activity against HCV genotype 1a infected in human HuH7 cells by replicon based assay [PMID: 25650256]
Huh-7 EC50 > 89 μM Antiviral activity against HCV genotype 1b infected in human HuH7 cells by replicon based assay [PMID: 25650256]

PSI-6206 Research Summary

This section summarizes 1 in vitro study of PSI-6206 from 1 published reference. In vitro models include CVB3-infected Vero cells.

PSI-6206 In Vitro Studies

PSI-6206 was evaluated in CVB3-infected Vero cells, with virus titres determined by the TCID50 assay. A result of 1.8-fold was reported at the highest concentration tested compared with untreated virus-infected cells. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Virus titres in infected Vero cells

Cell-based study · CVB3-infected Vero cells [1]

CVB3-infected Vero cells were treated with PSI-6206. Virus titres measured by the TCID50 assay had a reported result of 1.8-fold at the highest concentration tested compared with untreated virus-infected cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
virus titres were determined by the TCID50 assayviral titre 1.8-fold[1]

Literature-Reported Treatment Conditions

Exposure duration
24 hpi
Method
treated with dasabuvir and PSI-6206 at the indicated concentration, respectively
Vehicle
dimethyl sulfoxide (DMSO)
Co-treatment
Other interventions in this design: CVB3 MOI = 1. Compound effect isolated by the comparison: as compared to untreated virus-infected cells.
Reported limits
Not stated in the sentences used: dose.
Methods and source locations

Compound reported in the paper: PSI-6206

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Virus, cell lines and compounds (S3); Results > Dasabuvir and PSI-6206 are potent inhibitors of CVB3 replication (S25, S32, S33)

virus titres were determined by the TCID50 assay: virus titres were determined by the TCID50 assay; comparator: untreated virus-infected cells — Results > Dasabuvir and PSI-6206 are potent inhibitors of CVB3 replication (S25, S33)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 863329-66-2
Applications HCV RNA polymerase inhibitor
Formula C10H13FN2O5
Molecular Weight 260.22
Synonyms GS-331007; RO-2433
SMILES
C[C@]1([C@@H]([C@H](O[C@H]1N2C=CC(=O)NC2=O)CO)O)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 47 mg/mL (180.62 mM)
Water 47 mg/mL (180.62 mM)
Ethanol 22 mg/mL (84.54 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PSI-6206 Research References

  1. [1] Olasunkanmi OI, Zhong ZH. Combination of dasabuvir and PSI-6206 for the treatment of coxsackievirus B3 infection. J Virus Erad (2022). PMID: 35789934 DOI: 10.1016/j.jve.2022.100074 Source material

Added to your cart

View Cart Checkout
Loading...